In vivo and In vitro Drug Interactions Study of Glimepride with Atorvastatin and Rosuvastatin

被引:18
作者
Galani, V. J. [1 ,2 ]
Vyas, M.
机构
[1] AR Coll Pharm, Dept Pharmacol, Vallabh Vidyanagar 388120, Gujarat, India
[2] GH Patel Inst Pharm, Vallabh Vidyanagar 388120, Gujarat, India
关键词
Atorvastatin; drug interaction; glimepride; rosuvastatin;
D O I
10.4103/0975-1483.63169
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim of this investigation was to study the in vivo and in vitro drug interaction of glimepride with atorvastatin and rosuvastatin. In vitro drug interaction of glimepride with atorvastatin and rosuvastatin was studied using human pooled liver microsomes and evaluated using high performance liquid chromatography. In vivo pharmacokinetic drug interaction of glimepride (6 mg/kg) in coadministration with atorvastatin (60 mg/kg) and rosuvastatin (60 mg/ kg) were studied in rats and analyzed using liquid chromatography tandem mass spectrometry (LC- MS/MS). In in vitro study, atorvastatin decreased its own metabolism as well as the metabolism of glimepiride. Rosuvastatin coadministration with glimepride reduced the metabolism of glimepride and increased the metabolism of its own. In in vivo study, concentration in plasma, C max, AUC (0- t) and AUC (0-8) (area under the concentration- time curve, AUC) of glimepride was increased significantly in coadministration with atorvastatin whereas there was no significant change was observed in the case of coadministration with rosuvastatin. Half life (T 1/2) and volume of distribution (V d) of glimepride decreased significantly with both atorvastatin and rosuvastatin. Elimination rate constant, K el of glimepride increased significantly with both atorvastatin and rosuvastatin. Clearance (Cl) of glimepride decreased significantly but the decrease was more with atorvastatin than with rosuvastatin. It is concluded that glimepride metabolism is little affected by rosuvastatin in vitro, which agreed with the negligible interaction in in vivo study. Thus, from safety point of view rosuvastatin is better to prescribe as a coadministration therapy with glimepiride. On the other hand, atorvastatin could cause an increase in the bioavailability of glimepride per oral and also significantly decrease the metabolism of glimerpride in in vitro study. This may pose a positive implication in clinical practice.
引用
收藏
页码:196 / 200
页数:5
相关论文
共 15 条
[1]   A comparative evaluation of safety and efficacy of rosuvastatin, simvastatin, and atorvastatin in patients of type 2 diabetes mellitus with dyslipidemia [J].
Adsule, Samir Maruti ;
Baig, Mirza Shiraz ;
Gade, P. R. ;
Khandelwal, P. N. .
INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2009, 29 (02) :74-79
[2]   FIRST-TIME-IN-HUMAN DOSE SELECTION - ALLOMETRIC THOUGHTS AND PERSPECTIVES [J].
BOXENBAUM, H ;
DILEA, C .
JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 35 (10) :957-966
[3]   Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins) [J].
Igel, M ;
Sudhop, T ;
vonBergmann, K .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (05) :357-364
[4]   Efficacy and safe of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes - The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN) [J].
Knopp, Robert H. ;
D'Emden, Michael ;
Smilde, Johan G. ;
Pocock, Stuart J. .
DIABETES CARE, 2006, 29 (07) :1478-1485
[5]  
Krall LP, 1996, JOSLIN DIABETES MANU
[6]   Glimepiride - A review of its use in the management of type 2 diabetes mellitus [J].
Langtry, HD ;
Balfour, JA .
DRUGS, 1998, 55 (04) :563-584
[7]   Sense and nonsense in the prediction of drug-drug interactions [J].
Lin, JH .
CURRENT DRUG METABOLISM, 2000, 1 (04) :305-331
[8]   Atorvastatin: A hydroxymethylglutaryl-coenzyme A reductase inhibitor [J].
Malinowski, JM .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1998, 55 (21) :2253-2267
[9]   In vitro and in vivo antioxidant properties of gliclazide [J].
O'Brien, RC ;
Luo, M ;
Balazs, N ;
Mercuri, J .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2000, 14 (04) :201-206
[10]  
Proudfoot SG, 1999, ASSESSMENT BIOAVAILA, P174